Hemostatic and hematological abnormalities in gain-of-function fps/fes transgenic mice are associated with the angiogenic phenotype

Journal of Thrombosis and Haemostasis

Volumn 2, Issue 11, 2004, Pages 2009-2019

  Sangrar, W ^a,b   Senis, Y ^c   Samis, J A ^b   Gao, Y ^a   Richardson, M ^d   Lee, D H ^b   Greer, Peter A ^a,b  

^a QUEEN S UNIVERSITY   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

Angiogenesis; Coagulation; Fibrinolysis; fps fes; Hemangioma; Thrombocytopenia

Indexed keywords

PROTEIN KINASE FES; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ALLELE; ANEMIA; ANGIOGENESIS; ANIMAL CELL; ARTICLE; BLEEDING TENDENCY; BLEEDING TIME; BLOOD ANALYSIS; BLOOD CELL; CELL LINEAGE; DISSEMINATED INTRAVASCULAR CLOTTING; ERYTHROCYTE; FIBRINOLYSIS; FLOW CYTOMETRY; GENE MUTATION; GENETIC CODE; GENETIC GAIN; HEMATOLOGIC DISEASE; HEMATOLOGICAL PARAMETERS; HEMATOPOIESIS; HEMOSTASIS; HISTOLOGY; HYPOFIBRINOGENEMIA; IN VITRO STUDY; MOUSE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTHROMBIN TIME; THROMBIN TIME; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; TRANSGENIC MOUSE; TRANSMISSION ELECTRON MICROSCOPY; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANEMIA; ANIMALS; BLOOD COAGULATION DISORDERS; BLOOD PLATELETS; ENDOTHELIUM, VASCULAR; HEMOLYSIS; HEMOSTASIS; MICE; MICE, TRANSGENIC; NEOVASCULARIZATION, PHYSIOLOGIC; P-SELECTIN; PHENOTYPE; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-FES; THROMBOCYTOPENIA; THROMBOPOIESIS;

EID: 6944231935     PISSN: 15387933     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2004.00956.x     Document Type: Article

References (65)

1. Greer PA. Closing in on the biological functions of Fps/Fes and Fer. Nat Rev Mol Cell Biology 2002; 3: 278-89.
2. Aspenstrom P. A Cdc42 target protein with homology to the non-kinase domain of FER has a potential role in regulating the actin cytoskeleton. Curr Biol 1997; 7: 479-87.
3. Senis YA, Craig AWB, Greer PA. Fps/Fes and Fer protein-tyrosine kinases play redundant roles in regulating hematopoiesis. Exp Hematol 2003; 31: 673-81.
4. Greer P, Haigh J, Mbamalu G, Khoo W, Bernstein A, Pawson T. The Fps/Fes protein-tyrosine kinase promotes angiogenesis in transgenic mice. Mol Cell Biol 1994; 14: 6755-63.
5. Szlachetka DM. Kasabach-Merritt syndrome: a case review. Neonatal Netw 1998; 17: 7-15.
6. Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg 1982; 69: 412-22.
7. Verkarre V, Patey-Mariaud de Serre N, Vazeux R, Teillac-Hamel D, Chretien-Marquet B, Le Bihan C, Leborgne M, Fraitag S, Brousse N. ICAM-3 and E-selectin endothelial cell expression differentiate two phases of angiogenesis in infantile hemangiomas. J Cutan Pathol 1999; 26: 17-24.
8. Dosanjh A, Chang J, Bresnick S, Zhou L, Reinisch J, Longaker M, Karasek M. In vitro characteristics of neonatal hemangioma endothelial cells. similarities and differences between normal neonatal and fetal endothelial cells. J Cutan Pathol 2000; 27: 441-50.
9. Sangrar W, Mewburn J, Vincent S, Fisher J, Greer P. Vascular defects in gain-of-function fps/fes transgenic mice correlate with PDGF- and VEGF-induced activation of mutant Fps/Fes kinase in endothelial cells. J Thromb Haemost 2004; 2: 820-32.
10. Mochizuki Y, Nakamura T, Kanetake H, Kanda S. Angiopoietin 2 stimulates migration and tube-like structure formation of murine brain capillary endothelial cells through c-Fes and c-Fyn. J Cell Sci 2002; 115: 175-83.
11. Haigh J, McVeigh J, Greer P. The fps/fes tyrosine kinase is expressed in myeloid, vascular endothelial, epithelial, and neuronal cells and is localized in the trans-golgi network. Cell Growth Differ 1996; 7: 931-44.
12. Wang SJ, Greer P, Auerbach R. Isolation and propagation of yolk-sac-derived endothelial cells from a hypervascular transgenic mouse expressing a gain-of-function fps/fes proto-oncogene. In vitro Cell Dev Biol Anim 1996; 32: 292-9.
13. Dubois NA, Kolpack LC, Wang R, Azizkhan RG, Bautch VL. Isolation and characterization of an established endothelial cell line from transgenic mouse hemangiomas. Exp Cell Res 1991; 196: 302-13.
14. Kanda S, Lerner EC, Tsuda S, Shono T, Kanetake H, Smithgall TE. The nonreceptor protein-tyrosine kinase c-Fes is involved in fibroblast growth factor-2-induced chemotaxis of murine brain capillary endothelial cells. J Biol Chem 2000; 275: 10105-11.
15. Kanda S, Mochizuki Y, Miyata Y, Kanetake H. The role of c-Fes in vascular endothelial growth factor-A-mediated signaling by endothelial cells. Biochem Biophys Res Commun 2003; 306: 1056-63.
16. Haigh J, Ema M, Haigh K, Gertsenstein M, Greer P, Rossant J, Nagy A, Wagner EF. Activated Fps/Fes can functionally substitute for Flk1 deficiency in vascular development in vivo. Blood 2004; 103: 912-20.
17. Hackenmiller R, Kim J, Feldman RA, Simon MC. Abnormal Stat activation, hematopoietic homeostasis, and innate immunity in c-fes -/- mice. Immunity 2000; 13: 397-407.
18. Zirngibl RA, Senis Y, Greer PA. Enhanced endotoxin-sensitivity in Fps/Fes-null mice with minimal defects in hematopoietic homeostasis. Mol Cell Biol 2002; 22: 2472-86.
19. Sangrar W, Gao Y, Zirngibl R, Scott M, Greer P. The fps/fes proto-oncogene regulates hematopoietic lineage output. Exp Hematol 2003; 31:1259-67.
20. Keller P, Payne JL, Tremml G, Greer PA, Gaboli M, Pandolfi PP, Bessler M. FES-Cre targets phosphatidylinositol glycan class A (PIGA) inactivation to hematopoietic stem cells in the bone marrow. J Exp Med 2001; 194: 581-9.
21. Senis YA, Sangrar W, Zirngibl RA, Craig AWB, Lee DH, Greer PA. Fps/Fes and Fer nonreceptor protein-tyrosine kinases regulate collagen- and ADP-induced platelet aggregation. J Thrombosis Haemostasis 2003; 1: 1062-70.
22. Macart M, Koffi A, Henocque G, Mathieu JF, Guilbaud JC. Optimized microturbidimetric assay for fibrinogen. Clin Chem 1989; 35: 211-4.
23. Nagashima M, Yin ZF, Zhao L, White K, Zhu Y, Lasky N, Halks-Miller M, Broze GJ Jr, Fay WP, Morser J. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J Clin Invest 2002; 109: 101-10.
24. Ware J, Russell S, Ruggeri ZM. Generation and rescue of a murine model of platelet dysfunction: the Bernard-Soulier syndrome. Proc Natl Acad Sci USA 2000; 97: 2803-8.
25. Dubois-Stringfellow N, Kolpack-Martindale L, Bautch VL, Azizkhan RG. Mice with hemangiomas induced by transgenic endothelial cells: a model for the Kasabach-Merritt syndrome. Am J Pathol 1994; 144: 796-806.
26. Good TA, Carnazzo SF, Good R. Thrombocytopenia and giant hemangioma in infants. Am J Dis Child 1955; 90: 260-74.
27. Shim WK. Hemangiomas of infancy complicated by thrombocytopenia. Am J Surg 1968; 116: 896-906.
28. Drolet BA, Esterly NB, Frieden IJ. Hemangiomas in children. N Engl J Med 1999; 341: 173-81.
29. Kasabach H, Merritt K. Capillary hemangioma with extensive purpura: report of a case. Am J Dis Child 1940; 59: 1063-70.
30. Layendecker SJ, McDonald TP. The relative roles of the spleen and bone marrow in platelet production in mice. Exp Hematol 1982; 10: 332-42.
31. Larsen EC, Zinkham WH, Eggleston JC, Zitelli BJ. Kasabach-Merritt syndrome: therapeutic considerations. Pediatrics 1987; 79: 971-80.
32. Miller JG, Orton CI. Long term follow-up of a case of Kasabach-Merritt syndrome successfully treated with radiotherapy and corticosteroids. Br J Plast Surg 1992; 45: 559-61.
33. Esterly NB. Kasabach-Merritt syndrome in infants. J Am Acad Dermatol 1983; 8: 504-13.
34. Schulz AS, Urban J, Gessler P, Behnisch W, Kohne E, Heymer B. Anaemia, thrombocytopenia and coagulopathy due to occult diffuse infantile haemangiomatosis of spleen and pancreas. Eur J Pediatr 1999; 158: 379-83.
35. Pierce RN, Dunn L, Knisely AS. Consumptive coagulopathy in utero associated with multiple vascular malformations. Pediatr Pathol 1992; 12: 67-71.
36. Tanaka K, Shimao S, Okada T, Tanaka A. Kasabach-Merritt syndrome with disseminated intravascular coagulopathy treated by exchange transfusion and surgical excision. Dermatologica 1986; 173: 90-4.
37. Lang PG, Dubin HV. Hemangioma-thrombocytopenia syndrome: a disseminated intravascular coagulopathy. Arch Dermatol 1975; 111 105-7.
38. Enjolras O, Wassef M, Mazoyer E, Frieden IJ, Rieu PN, Drouet L, Taieb A, Stalder JF, Escande JP. Infants with Kasabach-Merritt syndrome do not have 'true' hemangiomas. J Pediatr 1997; 130: 631-40.
39. Sutherland D, Clark H. Hemangioma associated with thrombocytopenia. Am J Med 1962; 33: 150-7.
40. Seo, SK, Suh JC, Na GY, Kim IS, Sohn KR. Kasabach-Merritt syndrome: identification of platelet trapping in a tufted angioma by immunohistochemistry technique using monoclonal antibody to CD61. Pediatr Dermatol 1999; 16: 392-4.
41. Brizel HE, Raccuglia G. Giant hemangioma with thrombocytopenia: radioisotopic demonstration of platelet sequestration. Blood 1965; 26: 751-64.
42. Warrell RP Jr, Kempin SJ, Benua RS, Reiman RE, Young CW. Intratumoral consumption of indium-111 labeled platelets in a patient with hemangiomatosis and intravascular coagulation (Kasabach-Merritt syndrome). Cancer 1983; 52: 2256-60.
43. Hillman RS, Phillips LL. Clotting-fibrinolysis in a cavernous hemangioma. Am J Dis Child 1967; 113: 649-53.
44. Castoldi G. Erythrocytes. In: Zucker-Franklin, D, Greaves, MF, Grossi, CE, Marmont, AM, eds. Atlas of Blood Cells - Function and Pathology. Philadelphia: Lea & Febiger, 1981: p. 347-660.
45. Mohandas N, Phillips WM, Bessis M. Red blood cell deformability and hemolytic anemias. Semin Hematol 1979; 16: 95-114.
46. Ways P, Simon E. The role of serum in acanthocyte autohemolysis and membrane lipid composition. J Clin Invest 1964; 43: 1322-8.
47. Biemer JJ. Acanthocytosis - biochemical and physiological considerations. Ann Clin Lab Sci 1980; 10: 238-49.
48. Akashi K, Traver D, Miyamoto T, Weissman IL. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 2000; 404: 193-7.
49. Li J, Kuter DJ. The end is just the beginning: megakaryocyte apoptosis and platelet release. Int J Hematol 2001; 74: 365-74.
50. Subramaniam M, Frenette PS, Saffaripour S, Johnson RC, Hynes RO, Wagner DD. Defects in hemostasis in P-selectin-deficient mice. Blood 1996; 87: 1238-42.
51. Romo GM, Dong JF, Schade AJ, Gardiner EE, Kansas GS, Li CQ, McIntire LV, Berndt MC, Lopez JA. The glycoprotein Ib-IX-V complex is a platelet counterreceptor for P-selectin. J Exp Med 1999; 190: 803-14.
52. Frenette PS, Johnson RC, Hynes RO, Wagner DD. Platelets roll on stimulated endothelium in vivo: an interaction mediated by endothelial P-selectin. Proc Natl Acad Sci USA 1995; 92: 7450-4.
53. Frenette PS, Denis CV, Weiss L, Jurk K, Subbarao S, Kehrel B, Hartwig JH, Vestweber D, Wagner DD. P-Selectin glycoprotein ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet-endothelial interactions in vivo. J Exp Med 2000; 191: 1413-22.
54. Denis CV, Andre P, Saffaripour S, Wagner DD. Defect in regulated secretion of P-selectin affects leukocyte recruitment in von Willebrand factor-deficient mice. Proc Natl Acad Sci USA 2001; 98: 4072-7.
55. Denis C, Methia N, Frenette PS, Rayburn H, Ullman-Cullere M, Hynes RO, Wagner DD. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc Natl Acad Sci USA 1998; 95: 9524-9.
56. Pasyk KA, Grabb WC, Cherry GW. Cellular haemangioma: light and electron microscopic studies of two cases. Virchows Arch a Pathol Anat Histol 1982; 396: 103-26.
57. Yasunaga C, Sueishi K, Ohgami H, Suita S, Kawanami T. Heterogenous expression of endothelial cell markers in infantile hemangio-endothelioma: immunohistochemical study of two solitary cases and one multiple one. Am J Clin Pathol 1989; 91: 673-81.
58. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341: 586-92.
59. Mammen EF. Disseminated intravascular coagulation (DIC). Clin Lab Sci 2000; 13: 239-45.
60. Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86 1327-30.
61. Gando S, Kameue T, Nanzaki S, Nakanishi Y. Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome. Thromb Haemost 1996; 75: 224-8.
62. Horan JT, Francis CW. Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation. Semin Thromb Hemost 2001; 27: 657-66.
63. Okajima K, Sakamoto Y, Uchiba M. Heterogeneity in the incidence and clinical manifestations of disseminated intravascular coagulation. a study of 204 cases. Am J Hematol 2000; 65: 215-22.
64. Senis Y, Zirngibl R, McVeigh J, Haman A, Hoang T, Greer PA. Targeted disruption of the murine fps/fes proto-oncogene reveals that Fps/Fes kinase activity is dispensable for hematopoiesis. Mol Cell Biol 1999; 19: 7436-46.
65. Browder T, Folkman J, Pirie-Shepherd S. The hemostatic system as a regulator of angiogenesis. J Biol Chem 2000; 275: 1521-4.